Pralsetinib therapy shows high response in range of cancer patients with RET gene fusions
In a Phase I/II trial, cancer treatment with pralsetinib has produced high response rates in patients with RET gene fusions, regardless of tumor type, researchers reported on Aug.12,… read more.